Diagnostics Company SIRS-Lab insolvent
Investor search for Molecular Diagnostics Company started
At the end of December, SIRS-Lab requested the opening of insolvency proceedings because the public and private shareholders could not agree upon a further funding.
“SIRS-Lab has developed an innovative diagnostic technology for sepsis, also known as blood poisoning. At the end of last year, a current clinical study about the efficiency of the new pathogen test could successfully be finished. In order to bring the test on the market, further investment, on which the current shareholders cannot agree upon, is necessary. At short notice, we therefore are searching for investors for this very interesting diagnostics company. The first meetings with management and employees made me very confident to proceed with the company. The salaries of the 30 SIRS-Lab employees are currently secured through the insolvency compensation payment,“ comments Prof. Rolf Rattunde from Leonhardt Rechtsanwälte Erfurt.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.